Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved crawled date : 2021 - 06 - 25 save search
Lynk Pharmaceuticals Announced Clinical Approval in China of Its New Class I Drug LNK01003
Published: 2021-06-25 (Crawled : 13:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.26%
H: 1.13%
C: 0.78%
china drug approval
I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus
Published: 2021-06-25 (Crawled : 13:00) - biospace.com/
MOR | News | $18.07 0.17% 0.17% 130K
|
Health Technology
|
| O: 2.89%
H: 0.23%
C: -0.55%
IMAB | $1.805 0.28% 0.28% 110K
|
Health Technology
|
| O: -3.4%
H: 3.67%
C: -0.65%
phase 1 china trial approval lupus phase 1b phase 2b
CENTOGENE Announces Shareholders Approve All Resolutions at Annual General Meeting
Published: 2021-06-25 (Crawled : 11:00) - globenewswire.com
CNTG | $0.475 -1.04% -1.05% 19K
|
Commercial Services
|
| O: -0.58%
H: 4.36%
C: 4.27%
approval
UP Fintech Holding Limited’s Singapore Subsidiary Receives Approval-in-Principle Regarding Securities Trading and Clearing in Singapore
Published: 2021-06-25 (Crawled : 09:00) - globenewswire.com
TIGR | $3.35 -0.89% -0.9% 810K
|
Finance
|
| O: 3.05%
H: 3.72%
C: -2.17%
approval
CHMP Recommends Approval of RINVOQ® (upadacitinib) for the Treatment of Atopic Dermatitis
Published: 2021-06-25 (Crawled : 07:00) - prnewswire.com
ABBV | News | $167.83 -1.01% 0.0% 4M
|
Health Technology
|
| O: -1.6%
H: 0.61%
C: 0.07%
treatment dermatitis approval chmp atopic dermatitis
Libtayo® (cemiplimab) Approved by the European Commission for First-Line Treatment of Patients with Advanced Non-small Cell Lung Cancer with ≥50% PD-L1 Expression
Published: 2021-06-25 (Crawled : 06:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.55%
H: 0.68%
C: 0.57%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.16%
H: 1.64%
C: 1.28%
treatment lung cancer europe cancer
Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma
Published: 2021-06-25 (Crawled : 06:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.55%
H: 0.68%
C: 0.57%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.16%
H: 1.64%
C: 1.28%
immunotherapy europe therapy cell carcinoma
Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression
Published: 2021-06-25 (Crawled : 06:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.55%
H: 0.68%
C: 0.57%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.16%
H: 1.64%
C: 1.28%
treatment lung cancer europe cancer
Sanofi: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma
Published: 2021-06-25 (Crawled : 06:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.55%
H: 0.68%
C: 0.57%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.16%
H: 1.64%
C: 1.28%
immunotherapy europe therapy cell carcinoma
Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates
Published: 2021-06-25 (Crawled : 06:00) - globenewswire.com
BHC | $8.56 0.35% 0.0% 2M
|
Health Technology
|
| O: 0.44%
H: 1.19%
C: 0.2%
license approval
Gainers vs Losers
| 65% | 35% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 210M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.